We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sloning BioTechnology Starting Feasibility Study for bioMerieux
News

Sloning BioTechnology Starting Feasibility Study for bioMerieux

Sloning BioTechnology Starting Feasibility Study for bioMerieux
News

Sloning BioTechnology Starting Feasibility Study for bioMerieux

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sloning BioTechnology Starting Feasibility Study for bioMerieux"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sloning BioTechnology GmbH, provider of gene mutant libraries (SlonoMax™), will carry out a feasibility study together with bioMerieux. The aim of the project is to generate a large number of different gene variants of an essential enzyme to be used in diagnostic applications.

Sloning will use its Slonomics™ industrial scale gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study will enable bioMerieux to identify an enzyme with significantly enhanced characteristics.

“We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer.” stated Dr. Heinz Schwer, the company CEO.

Advertisement